Company
Palisade Bio
Advancing Next - Generation Precision Therapies
Also known as Palisade Bio, Inc
- Business model
- B2B
- Legal name
- Palisade Bio, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Palisade Bio is a clinical-stage biopharmaceutical company developing targeted oral therapies for immune-mediated and fibrotic diseases, including IBD.
Funding snapshot
- Total raised
- $57.3MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $4M2024-05-06
Funding rounds
- Round, 2024
- $4M2024-05-06, SEC form D sold, 1 investor
- Round, 2024
- $2.5M2024-02-01, SEC form D sold, 15 investors
- Round, 2023
- $4M2023-04-05, SEC form D sold, 9 investors
- Round, 2023
- $2.5M2023-01-04, SEC form D sold, 6 investors
- Round, 2022
- $2.4M2022-05-10, SEC form D sold, 5 investors
- Round, 2020
- $7.6M2020-01-22, SEC form D sold, 3 investors
- Round, 2017
- $42K2017-05-17, SEC form D sold, 2 investors
- Round, 2016
- $20M2016-12-12, SEC form D sold, 1 investor
- Round, 2016
- $1.1M2016-05-12, SEC form D sold, 3 investors
- Round, 2014
- $10M2014-10-28, SEC form D sold, 1 investor
- Round, 2013
- $1.8M2013-03-22, SEC form D sold, 3 investors
- Round, 2009
- $1.5M2009-12-30, SEC form D sold, 1 investor
Loading relationship preview